Histology-agnostic drugs: A paradigm shift – A narrative review
Histology-agnostic drugs: A paradigm shift – A narrative review Read More »
Dr. Patnaik shares her perspectives on START’s pivotal role in the development of new cancer drugs
A Marathon and a Sprint The process of developing and bringing new medicines to patients in need is oftentimes lengthy and complex, which is why anything that can be done to expedite this process is critical for patients who are waiting for new treatment options. In the case of B6A, Seagen’s investigational antibody-drug conjugate (ADC),
Dr. Emiliano Calvo Leads the Discussion of Next Generation Immunotherapy at ASCO 2023
2023 ASCO – Next Generation Immunotherapy Congratulations to Dr. Emiliano Calvo, Director of START Spain, for leading the discussion of Next Generation Immunotherapy agents on June 4th during the ASCO annual meeting. read Linked Post Here
Dr. Emiliano Calvo Leads the Discussion of Next Generation Immunotherapy at ASCO 2023 Read More »
